Glutaminsaeure-α-anilid | 199530-42-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Glutaminsaeure-α-anilid
• 英文别名: 5-anilino-4-azaniumyl-5-oxopentanoate
• CAS: 199530-42-2
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: JMFXUTJZDSYTEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  92.4
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] GLUTAMINE TRANSPORT INHIBITORS AND METHODS FOR TREATING CANCER<br/>[FR] INHIBITEURS DE TRANSPORT DE GLUTAMINE ET PROCÉDÉS DE TRAITEMENT DU CANCER
  申请人：UNIV VANDERBILT

  公开号：WO2018107173A1

  公开（公告）日：2018-06-14

  Novel compounds, compositions, and methods for modulating ASCT2 function in a patient in need thereof.

  用于调节ASCT2功能的新化合物、组合物和方法，适用于需要的患者。
• Glutamine transport inhibitors and methods for treating cancer
  申请人：Vanderbilt University

  公开号：US10793514B2

  公开（公告）日：2020-10-06

  The present disclosure provides compounds of formula: wherein R1, R2, and n are defined as set forth in the specification, and related aminobutanoic acids. The present disclosure also provides compositions comprising these compounds and methods for modulating ASCT2 function in a patient in need thereof.

  本公开提供了式化合物： 其中 R1、R2 和 n 的定义如说明书所述，以及相关的氨基丁酸。本公开还提供了包含这些化合物的组合物，以及在有需要的患者中调节 ASCT2 功能的方法。
• Glutamine Transport Inhibitors and Methods for Treating Cancer
  申请人：Vanderbilt University

  公开号：US20200095190A1

  公开（公告）日：2020-03-26

  The present disclosure provides compounds of formula: wherein R 1 , R 2 , and n are defined as set forth in the specification, and related aminobutanoic acids. The present disclosure also provides compositions comprising these compounds and methods for modulating ASCT2 function in a patient in need thereof.
• METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY
  申请人：New York University

  公开号：US20210361603A1

  公开（公告）日：2021-11-25

  The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; or combination(s) thereof.
• [EN] METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY<br/>[FR] MÉTHODES DE TRAITEMENT DE CANCERS AYANT UNE VOIE NRF2/KEAP1 DÉRÉGULÉE
  申请人：UNIV NEW YORK

  公开号：WO2018145090A1

  公开（公告）日：2018-08-09

  The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; an immune check-point inhibitor, an immune modulator, or combination(s) thereof.